Naloxone: Closing the Access Gap - Live Webinar on November 19, 2024 10AM ET
Learn about the opioid crisis and the importance of naloxone access. Discover pharmacy-driven initiatives to increase naloxone availability and reduce opioid overdose deaths.
About this webinar
Opioid overdose deaths in the United States have risen dramatically in the last decade, largely driven by illicit fentanyl and other synthetic opioids. Naloxone, a mu-opioid receptor antagonist, rapidly and safely reverses the effects of an opioid overdose. Increased access to naloxone has been identified by the US DHHS and the Surgeon General as a key initiative for reducing opioid overdose deaths. However, less than 1 in 10 patients who could benefit from naloxone have access to this life-saving antidote. Healthcare professionals can lead the way toward closing the naloxone access gap.
This activity provides participants with data describing opioid-related harms in the United States, discuss cutting-edge public health and pharmacy-driven initiatives for increasing access to naloxone and identify key research findings that pertain to strategies for identifying patients at risk for unintentional overdose and increasing access to life-saving harm reduction interventions.
At the conclusion of this continuing education activity, the participant will be able to:
Describe barriers to naloxone access and alternative distribution models in the United States.
Evaluate current strategies to expand access to naloxone, naloxone devices, and proposed alternative models.
Develop patient care strategies for increasing access to naloxone and other harm-reduction resources
Instructors
William Eggleston is an assistant professor at the Binghamton University School of Pharmacy & Pharmaceutical Sciences and a clinical toxicologist at SUNY Upstate Medical University and with the Upstate New York Poison Center. He received his PharmD from Wilkes University and completed a two-year fellowship in clinical toxicology and emergency medicine at SUNY Upstate Medical University and the Upstate New York Poison Center. He is the director for the Opioid Research Center for Central New York, and his research focuses on reducing patient harms associated with opioid use. He is also a member of the Board of Directors for the American Board of Applied Toxicology and the director for the joint clinical toxicology fellowship at the Binghamton University School of Pharmacy and the Upstate New York Poison Center.